

Welcome to today's FDA/CDRH Webinar

Thank you for your patience while additional time is provided for participants to join the call.

If you have not connected to the audio portion of the webinar, please do so now: U.S Callers Dial: 800-779-1537 International Callers Dial: 1-517-308-9336 Passcode:4492488



Acceptance of Data from Clinical Investigations for Medical Devices

John Doucet and Jayna Stohlman Clinical Trials Program Office of Device Evaluation

Center for Devices and Radiological Health

March 19, 2019



Publication Date: February 21, 2018

Final Rule

Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices

Associated Guidance

FDA Acceptance of Clinical Data to Support Medical

Device Applications and Submissions

Frequently Asked Questions

Effective Date: February 21, 2019

Purpose of Device Rule



- Update and clarify the requirements for FDA acceptance of clinical data
 - for all device application and submission types, and
 - for investigations conducted inside and outside the United States
- Expressly incorporate good clinical practice (GCP)
 - Ensure the quality and integrity of the data
 - Ensure the protection of human subjects
- Harmonize with drug regulations
- Ensure FDA's decisions are based on valid, ethically derived data.

Center for Devices and Radiological Health Vision Statement





Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world.

Agenda



- Background
- Requirements for Acceptance of Data From Device Clinical Investigations
- FDA Implementation and Recommendations
- Questions



Objectives

Understand the following elements:

- The purpose of the requirements for acceptance of data from device clinical investigations
- Documentation requirements from device clinical investigations to support premarket submissions
- Recommendations and resources for complying with the rule



Definitions

- Investigation research involving one or more subjects to determine the safety or effectiveness of a device [812.3(h)]
 - United States (US) investigation: conducted solely in US
 - Outside US (OUS) investigation: conducted solely outside the US
 - Multinational investigation: conducted at sites both within and outside the US
- Investigational Device Exemption (IDE) application: mechanism to request approval for a significant risk clinical investigation of an unapproved device or unapproved use of a device
- Marketing application or submission: Premarket Notification (510(k)), Request for De Novo Classification (De Novo), Premarket Approval Application (PMA), Product Development Protocol (PDP), Humanitarian Device Exemption (HDE)




CENTER FOR DEVICES & RADIOLOGICAL HEALTH

Background

Final Rule Timeline







Public Comments on the Proposed Rule

Key Feedback (13 entities)

- Application of the rule
 - Investigations within scope (e.g., Nonsignificant risk investigations, In Vitro Diagnostic (IVD) investigations using de-identified biospecimens)
- Implementation of the rule
 - Effective date
- International standards and other laws
 - Lack of a harmonized international good clinical practice (GCP) standard
 - Privacy laws that may vary by country
- Acceptance of data from noncompliant studies



FDA's Response to Public Comments

- Changes to the Final Rule
 - Adjusted supporting information requirements to vary by study risk
 - Delayed effective date (from 6 months to 1 year)
 - Added additional regulatory flexibility, such as a waiver provision
- Other Information in the Preamble
 - Clarified that FDA's policy, outlined in the FDA Guidance, "Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable," may be used to address informed consent for certain IVD studies using leftover, de-identified human specimens.



CENTER FOR DEVICES & RADIOLOGICAL HEALTH

Requirements for Acceptance of Data from Device Clinical Investigations

Scope of Final Rule



- 21 CFR parts 807, 812, and 814 have been amended to identify criteria for acceptance of clinical data for all premarket submissions
 - Investigational Device Exemption (IDE), Premarket Notification (510(k)), Request for De Novo Classification (De Novo), Premarket Approval Application (PMA), Product Development Protocol (PDP), Humanitarian Device Exemption (HDE)
- The rule applies to clinical investigations that begin (enroll their first subject) on or after February 21, 2019

Supporting Data vs. Supplementary Data

Supporting clinical data – Final Rule requirements apply

"...provided to support an IDE or device marketing application or submission; <u>for example</u>, when clinical data are submitted in:

- A 510(k) submission to demonstrate substantial equivalence,
- A PMA application to demonstrate a reasonable assurance of safety and effectiveness, or
- An HDE application to demonstrate reasonable assurance of safety and probable benefit."

Supplementary clinical data – Final Rule requirements do not apply

Good Clinical Practice (GCP) An Established Framework



GCP – "... a standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical investigations in a way that provides assurance that the data and results are credible and accurate and that the rights, safety, and well-being of subjects are protected."

Key Principles:

- Independent Ethics Committee (IEC)
 - Initial review and approval, continuing review
- Obtaining and documenting freely given informed consent prior to subject participation

FDA GCP Regulations



- Investigations conducted inside the U.S. comply with FDA GCP regulations including:
 - 21 CFR 812 Investigational Device Exemptions
 - 21 CFR 50 Protection for Human Subjects, Informed Consent (IC) Regulation
 - 21 CFR 56 Institutional Review Boards (IRBs)

Address data quality and integrity and protection of human subjects

Final Rule Requirements US Investigations



For acceptance of data that are from clinical investigations **conducted inside the United States**, the Final Rule requires that sponsors or applicants provide:

- A <u>statement</u> that *each* investigation was conducted in compliance with the applicable requirements in parts 21 CFR 50, 56, and 812
- If not conducted in compliance with these regulations, a brief statement of the reason for noncompliance

Final Rule Requirements OUS Investigations



- 1. A <u>statement</u> that *each* investigation was conducted in accordance with GCP.
 - If not conducted in accordance with GCP include either:
 - A <u>waiver request</u> in accordance with 812.28(c); or
 - A brief <u>statement</u> of the reason for not conducting the investigation in accordance with GCP and a <u>description</u> of steps taken to ensure that the data and results are credible and accurate and that the rights, safety and well-being of subjects have been adequately protected.
- 2. Supporting information to demonstrate conformance with GCP

OUS Investigations Closer look at required Supporting Information



- Names and addresses of investigators and research facilities
- Investigator qualifications
- Summary of protocol and study results
- Description of the device
- Discussion demonstrating that the data and information constitute valid scientific evidence
- Adequately constituted IEC

OUS Investigations Closer look at required Supporting Information



- Summary of IEC's decision to approve or modify and approve the clinical investigation
- Description of how informed consent was obtained
- Description of incentives provided to subjects
- Description of how the study was monitored
- Investigator training and commitments

Requirements are not intended to be duplicative with information already included in the submission and may be cross-referenced

OUS Investigations Supporting Information to Submit to FDA



- Based on sponsor's or applicant's risk determination
 - Sponsor/applicant maintains documentation of the rationale for their determination
- Submission requirements vary by risk
 - Significant Risk investigations: Submission of all required elements
 - Non-significant Risk investigations: Submission of some elements while others are to be available for agency review upon request
 - Exempt investigations: Some elements are to be available for agency review upon request

Regulatory Flexibility



- 1. Sponsors and applicants may choose a GCP standard that meets the regulatory definition
- 2. Allowance for explaining why GCP was not followed and other measures used to ensure data integrity and subject protections
- 3. Waiver(s) may be requested in accordance with §812.28(c)

Summary of Provisions



For investigations that enroll the first subject on or after February 21, 2019

	US	OUS	Multinational
IDE 510(k) De Novo	Statement of compliance* with:	 Statement of conformance with GCP** 	 US sites - Statement of compliance with FDA regulations*
PMA HDE PDP	21 CFR 50 21 CFR 56 21 CFR 812	2. Supporting information to demonstrate conformance**	 OUS sites - Statement of conformance with GCP and supporting information**

* Or a rationale for noncompliance

** Or a rationale for noncompliance or a waiver request



CENTER FOR DEVICES & RADIOLOGICAL HEALTH

Implementation and Recommendations

Acceptance Review



The following guidances and associated acceptance checklists have been updated to incorporate provisions of the Final Rule:

- Refuse to Accept Policy for 510(k)s
- <u>Acceptance and Filing Reviews for Premarket Approval</u>
 <u>Applications (PMAs)</u>

Acceptance Review An Example



	Yes	No	N/A	*Page #
tements of Compliance for Clinical Investigations				
lect "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to nonstrate substantial equivalence.				
r multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) uld be addressed for the US sites and part (ii) should be tressed for the OUS sites. 21 CFR 812.28 applies to all IS clinical investigations that enroll the first subject on or er February 21, 2019.				
ase refer to the guidance document entitled " <u>Acceptance</u> Clinical Data to Support Medical Device Applications and <u>omissions - Frequently Asked Questions</u> ," for more ormation				
For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. <u>OR</u> The submission includes a brief statement of the reason for noncompliance with 21 CFR parts 50,56 and 812.				
Select "N/A" if the clinical investigations were conducted solely OUS.				
For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). OR The submission includes a waiver request in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the data and results are credible and accurate and that the rights, safety, and well-being of subjects have been				
	 ect "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to constrate substantial equivalence. multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) uld be addressed for the US sites and part (ii) should be ressed for the OUS sites. 21 CFR 812.28 applies to all S clinical investigations that enroll the first subject on or r February 21, 2019. ase refer to the guidance document entitled "Acceptance Clinical Data to Support Medical Device Applications and missions - Frequently Asked Ouestions," for more rmation For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. <u>OR</u> The submission includes a brief statement of the reason for noncompliance with 21 CFR parts 50,56 and 812. Select "N/A" if the clinical investigations were conducted Solely OUS. For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted Solely OUS. For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). <u>OR</u> The submission includes a brief statement of the reason for not conducting the investigation in accordance with 21 CFR 812.28(c). <u>OR</u> The submission includes a brief statement of the reason for not conducting the investigation in accordance with 21 CFR 812.28(c). <u>OR</u> The submission includes a brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the 	eet "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to constrate substantial equivalence. multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) uild be addressed for the US sites and part (ii) should be tressed for the OUS sites. 21 CFR 812.28 applies to all S clinical investigations that enroll the first subject on or r February 21, 2019. ase refer to the guidance document entitled "Acceptance Clinical Data to Support Medical Device Applications and missions - Frequently Asked Questions," for more rmation For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. Select "N/A" if the clinical investigations were conducted solely OUS. For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). OR The submission includes a waiver request in accordance with 21 CFR 812.28(c). OR The submission includes a waiver request in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducted GCP as described in 21 CFR 812.28(c). OR The submission includes a statement that the clinical investigations were conducted in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement o	eet "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to constrate substantial equivalence. multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) uhld be addressed for the US sites and part (ii) should be tressed for the OUS sites. 21 CFR 812.28 applies to all S clinical investigations that enroll the first subject on or r February 21, 2019. ase refer to the guidance document entitled "Acceptance Clinical Data to Support Medical Device Applications and missions - Frequently Asked Ouestions," for more rmation For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. Select "N/A" if the clinical investigations were conducted solely OUS. For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted solely OUS. For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). OR The submission includes a brief statement of the reason for no conducted GCP as described in 21 CFR 812.28(a)(1). OR The submission includes a brief statement of the reason for no conducting the investigation in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducting the investigation in accordance with 21 CFR 812.28(c). <td>iew "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to sonstrate substantial equivalence. multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) and be addressed for the US sites and part (ii) should be ressed for the OUS sites. 21 CFR 812.28 applies to all S clinical investigations that enroll the first subject on or r February 21, 2019. nse refer to the guidance document entitled "Acceptance "Initial Data to Support Medical Device Applications and missions - Frequently Asked Ouestions." for more ormation For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. OR The submission includes a brief statement of the reason for noncompliance with 21 CFR as a statement that the clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted as a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). OR The submission includes a waiver request in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducted in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducted a brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the</td>	iew "N/A" if the submission does not contain any clinical a from investigations (as defined in 21 CFR 812.3(h)) to sonstrate substantial equivalence. multicenter clinical investigations involving both United tes (US) and outside United States (OUS) sites, part (i) and be addressed for the US sites and part (ii) should be ressed for the OUS sites. 21 CFR 812.28 applies to all S clinical investigations that enroll the first subject on or r February 21, 2019. nse refer to the guidance document entitled "Acceptance "Initial Data to Support Medical Device Applications and missions - Frequently Asked Ouestions." for more ormation For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. OR The submission includes a brief statement of the reason for noncompliance with 21 CFR as a statement that the clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted as a statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1). OR The submission includes a waiver request in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducted in accordance with 21 CFR 812.28(c). OR The submission includes a brief statement of the reason for not conducted a brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the

Scope

U.S. Investigations

OUS Investigations

[https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm315014.pdf]

conducted solely inside the US.

Acceptance Review Scope



		Yes	No	N/A	*Page #
c.	Statements of Compliance for Clinical Investigations				
	Select "N/A" if the submission does not contain any clinical data from investigations (as defined in 21 CFR 812.3(h)) to demonstrate substantial equivalence.				
	For multicenter clinical investigations involving both United States (US) and outside United States (OUS) sites, part (i) should be addressed for the US sites and part (ii) should be addressed for the OUS sites. 21 CFR 812.28 applies to all OUS clinical investigations that enroll the first subject on or after February 21, 2019.				
	Please refer to the guidance document entitled " <u>Acceptance</u> of Clinical Data to Support Medical Device Applications and <u>Submissions - Frequently Asked Questions</u> ," for more information				

- Defines applicability
- Includes reference to effective date
- Describes which of the subsequent questions apply (U.S., OUS, or multinational investigations)
- Provides link to the FAQ Guidance

Acceptance Review U.S. Investigations



		Yes	No	N/A	*Page #
i.	For each clinical investigation conducted in the US, the submission includes a statement of compliance with 21 CFR parts 50, 56, and 812. <u>OR</u> The submission includes a brief statement of the reason for noncompliance with 21 CFR parts 50,56 and 812. <i>Select "N/A" if the clinical investigations were conducted solely OUS.</i>				

Acceptance Review OUS Investigations



	Yes	No	N/A	*Page #
 For each clinical investigation conducted OUS, the submission includes a statement that the clinical investigations were conducted in accordance with goo clinical practice (GCP) as described in 21 CFR 812.28(a)(1). <u>OR</u> The submission includes a waiver request in accordance with 21 CFR 812.28(c). <u>OR</u> The submission includes a brief statement of the reaso for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the data and results are credible and accurate and that the rights, safety, and well-being of subjects have been adequately protected. 	nce on h e			

Waiver Requests



There may be situations where investigations conducted OUS are not able to fully conform to GCP and/or are not able to demonstrate conformity to GCP, as described by 21 CFR 812.28(a).



A sponsor or applicant may ask the FDA to waive any applicable requirements by submitting a waiver request prior to or within an IDE or marketing submission or application

Waiver Requests What to Submit



A Waiver Request is required to include at least one of the following:

- i. An explanation why the sponsor's or applicant's compliance with the requirement is unnecessary or cannot be achieved;
- ii. A description of an <u>alternative submission or course of</u> <u>action</u> that satisfies the purpose of the requirement; or

iii. Other information justifying a waiver

Waiver Requests When and How to Submit



As part of a premarket submission:

- In an IDE, or an Amendment or Supplement to an IDE;
- In a device marketing application or submission, or in an Amendment or Supplement to a device marketing application or submission;

As a standalone Waiver Request:

- Submit to Document Control Center
- Clearly identify that the submission is a Waiver Request in accordance with 21 CFR 812.28(c)

Waiver Requests How we communicate decisions



Within a marketing application or submission, or an IDE (report of prior investigations)	 No formal communication with respect to whether a waiver request was granted or denied, unless the decision impacts FDA's acceptance of the data and results in deficiencies to be addressed, in which case information will be provided in deficiency letters. Final decision on a submission or application does not imply whether or not a waiver request was granted or denied.
 Other Waiver Requests: In a "pre-submission"; or In a IDE submission (when pertaining to the subject IDE) 	 Decision to grant or deny the waiver request is communicated in a letter.

Determination on acceptability of waiver will be determined on a case-by-case basis.

Recommendations for Submissions



Clearly identify in the premarket submission or application:

- Whether it contains data from OUS clinical investigations that are subject to 21 CFR 812.28 (cover letter)
- Location of all required elements under 21 CFR 812.28:
 - Within the subject submission or application
 - Cross-reference to previously submitted materials
 - Page references to respective clinical investigation reports, etc.
- Whether the submission includes statements of the reasons for not conducting the investigation in accordance with GCP, or a waiver is being requested or was previously granted

Q-Submission Program



Contains Nonbinding Recommendations

Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff

Guidance for Industry and Food and Drug Administration Staff

Document issued on September 29, 2017

Document originally issued on February 18, 2014

For questions regarding this document, contact the CDRH Program Operations Staff (POS) at 301-796-5640. For questions regarding submissions to the Center for Biologics Evaluation and Research (CBER), contact CBER's Office of Communication, Outreach and Development at 1-800-835-4709 or 240-402-8010.

S. FOOD & DRUG

MINISTRATION

U.S. Department of Health and Human Services Food and Drug Administration

Center for Devices and Radiological Health

Center for Biologics Evaluation and Research

- Study Risk Determination for OUS investigations
- Pre-Submission: General Questions about compliance

Conclusions



- The final rule provides clarity and consistency for acceptance of clinical data for all premarket application and submission types for both U.S. and OUS investigations.
 - Applies to investigations beginning on or after February 21, 2019
- The rule requires that data submitted from clinical investigations be from investigations conducted in accordance with GCP.
- It is the FDA's intent to ensure that quality data are used to support IDEs and marketing applications and submissions, and that the rights, safety, and well-being of human subjects have been adequately protected.





- Guidance
 - Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions
 - <u>Guidance on Informed Consent for In Vitro Diagnostic Device Studies</u>
 <u>Using Leftover Human Specimens that are Not Individually Identifiable</u>

GCP Standards

- ISO 14155: Clinical investigation of medical devices for human subjects
 Good clinical practice
- ICH E6: Good Clinical Practice: Consolidated Guidance
- FDA Help
 - <u>CDRHClinicalEvidence@fda.hhs.gov</u>

Questions?



Division of Industry and Consumer Education: DICE@fda.hhs.gov

Slide Presentation, Transcript and Webinar Recording will be available at:

http://www.fda.gov/training/cdrhlearn

Under the heading: How to Study and Market Your Device; Subheading: Clinical Studies/Investigational Device Exemption (IDE)

Please complete a short survey about your FDA CDRH webinar experience. The survey can be found at www.fda.gov/CDRHWebinar immediately following the conclusion of the live webinar.